Recurrent Diffuse Midline Glioma, H3 K27-Altered
1 clinical trials · Condition
◉ Watch Recurrent Diffuse Midline Glioma, H3 K27-Altered
| Record | Firm | Date |
|---|---|---|
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
Track Recurrent Diffuse Midline Glioma, H3 K27-Altered automatically
Every clearance here is in the API, with alerts when new ones post.